Evaluation of 600 mg/m2 cytarabine arabinoside as treatment for meningoencephalomyelitis of unknown origin in 43 dogs
Open Access
- 21 January 2026
- journal article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 40 (1)
Abstract
Background: Cytarabine arabinoside (CA) is commonly used at 200 mg/m2 to treat dogs with meningoencephalomyelitis of unknown origin (MUO); use of higher doses is anecdotally reported. Hypothesis/Objectives: To describe the clinical outcome in 43 dogs with MUO receiving 600 mg/m2 CA. We hypothesized that high dose CA would be well tolerated, that the majority of dogs with MUO would achieve sustained remission, and that dogs with spinal cord-only MUO or presumptive necrotizing meningoencephalitis (NME) would carry a more guarded prognosis. Animals: Forty-three client-owned dogs with MUO. Methods: Retrospective observational study. Medical records were reviewed at a private practice over a 2.5-year period to identify dogs with MUO with clinical signs 24 months (median 1027 days, range 770–1277 days). Thirteen out of forty-three (30%) dogs were euthanized due to poor disease control (median 17 days, range 1–340 days), including 5/10 (50%) dogs with spinal cord only MUO and 5/5 (100%) dogs with presumptive NME. No serious adverse events were noted with 600 mg/m2 CA. Conclusions and clinical importance: Six hundred mg/m2 CA was well tolerated and effectively controlled disease in most dogs with MUO. Response rate was lower for dogs with spinal cord MUO or presumptive NME.Keywords
This publication has 54 references indexed in Scilit:
- Clinical Presentation, Diagnostic Findings, and Long-term Survival Time in 182 Dogs With Meningoencephalitis of Unknown Origin From Central Europe That Were Administered Glucocorticosteroid MonotherapyTopics in Companion Animal Medicine, 2021
- Immune-Mediated Central Nervous System Disease—Current Knowledge and RecommendationsTopics in Companion Animal Medicine, 2019
- Clinical presentation, diagnostic findings, prognostic factors, treatment and outcome in dogs with meningoencephalomyelitis of unknown origin: A reviewThe Veterinary Journal, 2019
- Effect of a constant rate infusion of cytosine arabinoside on mortality in dogs with meningoencephalitis of unknown originThe Veterinary Journal, 2016
- Treatment of canine meningoencephalomyelitis of unknown aetiology with mycophenolate mofetil and corticosteroids: 25 cases (2007–2012)Veterinary Medicine and Science, 2016
- Efficacy of glucocorticoid monotherapy for treatment of canine meningoencephalomyelitis of unknown etiology: a prospective study in 16 dogsVeterinary Medicine and Science, 2015
- Perspectives on Meningoencephalomyelitis of Unknown OriginVeterinary Clinics of North America: Small Animal Practice, 2014
- Clinical findings and treatment of non-infectious meningoencephalomyelitis in dogs: A systematic review of 457 published cases from 1962 to 2008The Veterinary Journal, 2010
- Inflammatory Intracranial Diseases: The Meningoencephalitides2007
- Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogsCancer Chemotherapy and Pharmacology, 1991